You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 10,507,243


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,507,243
Title:Nanoparticle complexes of rituximab, albumin and pacltaxel
Abstract: Described are stable nanoparticle complexes comprising paclitaxel, albumin and rituximab. The nanoparticle complexes are suitable for the treatment of cancer.
Inventor(s): Markovic; Svetomir N. (Rochester, MN), Nevala; Wendy K. (Rochester, MN)
Assignee: Mayo Foundation for Medical Education and Research (Rochester, MN)
Application Number:15/414,526
Patent Claims:1. An antibody-albumin nanoparticle complex, the nanoparticle complex comprising albumin, a rituximab antibody, and paclitaxel, wherein the nanoparticle complex has been pre-formed in vitro by mixing an aqueous albumin-paclitaxel nanoparticle with the antibody under conditions to form the nanoparticle complex, such that the nanoparticle complex has CD20 binding specificity, said complex having a diameter of between 0.1 .mu.m and 1 .mu.m.

2. The antibody-albumin nanoparticle complex of claim 1, further comprising an alkylating agent.

3. The antibody-albumin nanoparticle complex of claim 2, wherein said alkylating agent is a platinum compound.

4. The antibody-albumin nanoparticle complex of claim 3, wherein said platinum compound is carboplatin.

5. The antibody-albumin nanoparticle complex of claim 1, said complex having a diameter of between 0.1 .mu.m and 0.9 .mu.m.

6. The antibody-albumin nanoparticle complex of claim 1, said complex having a diameter of between 0.1 .mu.m and 0.3 .mu.m.

7. The antibody-albumin nanoparticle complex of claim 1, wherein the ratio of albumin-paclitaxel nanoparticle to antibody is between 5:1 and 1:2.5.

8. A pharmaceutical composition comprising a pharmaceutically acceptable carrier antibody-albumin nanoparticle complexes, wherein said antibody-albumin nanoparticle complexes comprise albumin, a rituximab antibody, and paclitaxel, wherein the nanoparticle complexes have been pre-formed in vitro by mixing aqueous albumin-paclitaxel nanoparticles with the antibody under conditions to form the nanoparticle complex, such that the nanoparticle complexes have binding specificity, said complexes having an average diameter of between 0.1 .mu.m and 1 .mu.m.

9. The pharmaceutical composition of claim 8, wherein said composition or said antibody-albumin nanoparticle complexes comprise an alkylating agent.

10. The pharmaceutical composition of claim 9, wherein said alkylating agent is a platinum compound.

11. The pharmaceutical composition of claim 10, wherein said platinum compound is carboplatin.

12. The pharmaceutical composition of claim 8, wherein the average diameter of said complexes is between 0.1 .mu.m and 0.9 .mu.m.

13. The pharmaceutical composition of claim 8, wherein the average diameter of said complexes is between 0.1 .mu.m and 0.3 .mu.m.

14. The pharmaceutical composition of claim 8, wherein the ratio of albumin-paclitaxcel nanoparticle to antibody is between 5:1 and 1:2.5.

15. A method of making an antibody-albumin nanoparticle complex, the method comprising mixing in vitro an aqueous albumin-paclitaxel nanoparticle with a rituximab antibody under conditions to form the nanoparticle complex, wherein said complexes have an average diameter of between 0.1 .mu.m and 1 .mu.m.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.